A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 16, 2021

Primary Completion Date

October 22, 2024

Study Completion Date

October 22, 2024

Conditions
Chronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
Interventions
DRUG

tafasitamab

tafasitamab will be administered at a protocol defined dose once a week for cycles 1-3 and every other week from cycle 4 until progression.

DRUG

parsaclisib

parsaclisib will be administered at protocol defined dose for cycles 1 through disease progression.

Trial Locations (50)

11042

Clinical Research Alliance, New Hyde Park

18016

Hospital Universitario San Cecilio, Granada

19107

Jefferson University Hospitals, Philadelphia

20089

Irccs Istituto Clinico Humanitas, Rozzano

20133

Fondazione Irccs Istituto Nazionale Dei Tumori, Milan

20162

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan

20817

Cancer Center For Blood Disorders, Bethesda

28041

Hospital Universitario 12 de Octubre, Madrid

28050

Centro Integral Oncologico Clara Campal (Ciocc), Madrid

28222

Hospital Puerta de Hierro, Majadahonda

28223

Hospital Universitario Quironsalud Madrid, Madrid

29609

University Hospital Brest, Brest

33011

Hospital Universitario Central de Asturias, Oviedo

35205

University of Alabama At Birmingham Comprehensive Cancer Center, Birmingham

35392

Justus-Liebig University, Giessen

37007

Hospital Clinico Universitario de Salamanca, Salamanca

39008

Hospital Universitario Marques de Valdecilla, Santander

40138

S Orsolas University Hospital Seragnoli Institute of Hematology, Bologna

40202

Norton Cancer Institute, Louisville

41015

Hospital Universitario Virgen Del Rocio, Seville

43210

Ohio State University, Columbus

44093

Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hotel-Dieu, Nantes

46014

Hospital General Universitario de Valencia, Valencia

46237

Indiana Blood and Marrow Transplantation, Indianapolis

46250

Community Health Network, Inc., Indianapolis

47014

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori, Meldola

48109

University of Michigan, Ann Arbor

48121

Ospedale Santa Maria Delle Croci, Ravenna

55131

Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii, Mainz

56126

Azienda Ospedaliero Universitaria Pisana, Pisa

76038

Centre Henri Becquerel, Rouen

79106

University Medical Center Freiburg, Freiburg im Breisgau

80131

Istituto Nazionale Tumori Irccs Fondazione Pascale, Naples

90089

University of Southern California, Los Angeles

90146

Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello, Palermo

94805

Institut Gustave Roussy, Villejuif

97080

University Hospital Wurzburg, Würzburg

A-4020

Ordensklinikum Linz Gmbh Elisabethinen, Linz

05020

Landeskrankenhaus Salzburg, Salzburg

01140

Hanusch-Krankenhaus Der Wiener Gebietskrankenkasse, Vienna

B-1070

Institut Jules Bordet, Brussels

06000

Grand Hospital de Charleroi, Charleroi

02650

Universitair Ziekenhuis Antwerpen (Uza), Edegem

08500

Az Groeninge Campus Kennedylaan, Kortrijk

03000

Universitair Ziekenhuis (Uz) Leuven, Leuven

08800

AZ DELTA, Roeselare

03010

Hospital General Unviersitario de Alicante, Alicante

08035

Hospital General Universitario Vall D Hebron, Barcelona

08036

Hopital Sant Pau, Barcelona

08908

Ico Institut Catala D Oncologia, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT04809467 - A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter